Menu Search
Equities

NextCure Inc

2US:BER

NextCure Inc

Actions
  • Price (EUR)1.20
  • Today's Change-0.052 / -4.14%
  • Shares traded--
  • 1 Year change+15.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year NextCure Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 74.73m to a smaller loss of 62.72m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-47.88%
Return on equity-54.74%
Return on investment-51.64%
More ▼

Cash flow in USDView more

In 2023, cash reserves at NextCure Inc fell by 13.55m. However, Cash Flow from Investing totalled 39.27m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 52.97m for operations while cash generated from financing totalled 154.00k.
Cash flow per share-2.08
Price/Cash flow per share--
Book value per share3.05
Tangible book value per share3.05
More ▼

Balance sheet in USDView more

NextCure Inc uses little or no debt in its capital structure.
Current ratio8.35
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.